Uniqure BV of the Netherlands, which is the first company with a licensed gene therapy, expects to raise about $81.9 million from an initial public offering of its shares on the Nasdaq over-the-counter market in the US. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
